Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Consumer Healthcare Inc.

https://www.prestigebrands.com/

Latest From Prestige Consumer Healthcare Inc.

With TheraTears, Prestige Consumer Sees Way To Boost Guidance Despite COVID, Cost Uncertainties

More than 17% growth in consumer health product sales in latest quarter on top of adding TheraTears brands to its lineup at start of current quarter outweighs potential headwinds from costs and changes in consumer spending, Prestige Consumer executives say.

Business Strategies Consumer

US Q2 Consumer Health Earnings Preview: Will More Favorable Year-Ago Comparisons Help?

April-June sales of OTC drugs, supplements and personal care products likely will show at least notable and potentially strong increases from year-ago period when consumers slowed spending after splurging during 2020 Q1 as novel coronavirus pandemic sent shockwaves through the marketplace.

Consumer Sales & Earnings

Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn't

Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.

OTC Drugs Dietary Supplements

Seeing Light At End Of Pandemic Tunnel, Prestige Consumer Healthcare Raises Earnings Guidance

Prestige Consumer Healthcare prepares to “lap the effects” of COVID-19 disruption on, estimating its fiscal year 2021 sales will reach $935m, ahead of earlier projections, and maintaining long-term organic growth targets of 2%-3%.

See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Prestige Brands, Inc.
UsernamePublicRestriction

Register